Nonclear cell renal cell carcinoma (nccRCC) is a heterogeneous group of primary kidney tumors. The aim of the present retrospective study was to analyze outcomes of patients with nccRCC treated with tyrosine-kinase inhibitors (TKIs) based on a national registry.
The registry contained evaluable data of 93 nccRCC patients treated with first-line TKIs, including 87 patients with papillary renal cell carcinoma (RCC) and 6 patients with chromophobe RCC. The control cohort consisted of 1,788 patients with clear-cell RCC treated with first-line TKIs. Multivariable Cox proportional hazard model was used to evaluate the effect of potential prognostic factors on the survival measures.
Median progression-free survival was 11.8 and 6.5 months in the clear cell renal cell carcinoma and nccRCC patients, respectively (P = 0.018), and median overall survival was 33.2 and 22.0 months, respectively (P = 0.007). In the multivariate analysis, independent factors associated with inferior progression-free survival included high tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, and sunitinib (as opposed to pazopanib) as first-line targeted therapy. Independent predictors of inferior overall survival included nonclear cell histology, tumor grade, worse Memorial Sloan Kettering Cancer Center risk group, absence of nephrectomy, older age, and sunitinib as first-line targeted therapy.
The present retrospective, registry-based study confirms that patients with nccRCC treated with TKIs have worse clinical outcomes compared to clear cell renal cell carcinoma patients with similar baseline characteristics.
Urologic oncology. 2019 Jan 22 [Epub ahead of print]
Alexandr Poprach, Kristina Rumanova, Radek Lakomý, Renata Chloupková, Michal Stanik, Tomas Pokrivcak, Igor Kiss, Ondrej Slaby, Hana Studentova, Bohuslav Melichar, Jaroslav Juracek, Ondrej Fiala, Jindrich Kopecky, Katerina Kopeckova, Milada Zemanova, Tomas Buchler
Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic., Institute of Biostatistics and Analyses, Faculty of Medcine, Masaryk University, Brno, Czech Republic., Department of Urologic Oncology, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic., Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic., Department of Oncology, University Hospital, Pilsen, Czech Republic., University Hospital in Hradec Králové, Hradec Králové, Czech Republic., Department of Oncology, Motol University Hospital and Charles University Second Faculty of Medicine, Prague, Czech Republic., Department of Oncology, General University Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic., Department of Oncology, First Faculty of Medicine, Thomayer University Hospital and Charles University, Prague, Czech Republic. Electronic address: .